Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
The market size of Aspart in India is currently estimated over Rs. 260 crore with only 2 players
Tremelimumab (Imjudo) in combination with Durvalumab (Imfinzi) is indicated for the treatment of patients with unresectable hepatocellular carcinoma
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by RSV in children at high risk for RSV disease
Bumetanide Injection USP (RLD Bumex) had estimated annual sales of USD 20 million in the U.S.
The new facility further improves the operational efficiency and readies the site for the completion of the new large-scale production plant
ForDoz Pharma Corporation, USA (ForDoz) received an approval for its ANDA from the USFDA
The approval further adds to Biocon’s portfolio of complex drug products
Subscribe To Our Newsletter & Stay Updated